ArticleJournal of biomedical materials research. Part B, Applied biomaterials2018
An engineered macroencapsulation membrane releasing FTY720 to precondition pancreatic islet transplantation.
Article in Journal of biomedical materials research. Part B, Applied biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Advancing Type 1 Diabetes Treatment: 3 PM-Oriented Innovations in Islet Transplantation and Biomaterial Engineering.Diabetes/metabolism research and reviews · 2026Review
- Cell macroencapsulation devices in contemporary research: A systematic review.Regenerative therapy · 2025Review
- Exosomes as therapeutic and drug delivery vehicle for neurodegenerative diseases.Journal of nanobiotechnology · 2024Review
- Successful Islet Transplantation Into a Subcutaneous Polycaprolactone Scaffold in Mice and Pigs.Transplantation direct · 2023Article
- The PI3K/AKT signalling pathway in inflammation, cell death and glial scar formation after traumatic spinal cord injury: Mechanisms and therapeutic opportunities.Cell proliferation · 2022Review
- Nanofiber curvature with Rho GTPase activity increases mouse embryonic fibroblast random migration velocity.Integrative biology : quantitative biosciences from nano to macro · 2021Article
- Early-life fingolimod treatment improves intestinal homeostasis and pancreatic immune tolerance in non-obese diabetic mice.Acta pharmacologica Sinica · 2021Article
- Local Immunomodulatory Strategies to Prevent Allo-Rejection in Transplantation of Insulin-Producing Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Exosomes Derived from Nerve Stem Cells Loaded with FTY720 Promote the Recovery after Spinal Cord Injury in Rats by PTEN/AKT Signal Pathway.Journal of immunology research · 2021Article
- Integration of Islet/Beta-Cell Transplants with Host Tissue Using Biomaterial Platforms.Endocrinology · 2020Review
- Engineering Strategies to Improve Islet Transplantation for Type 1 Diabetes Therapy.ACS biomaterials science & engineering · 2020Article
- Aligned Fingolimod-Releasing Electrospun Fibers Increase Dorsal Root Ganglia Neurite Extension and Decrease Schwann Cell Expression of Promyelinating Factors.Frontiers in bioengineering and biotechnology · 2020Article
- Engineering the vasculature for islet transplantation.Acta biomaterialia · 2019Review
- Local delivery of FTY720 and NSCs on electrospun PLGA scaffolds improves functional recovery after spinal cord injury.RSC advances · 2019Article
- Engineering immunomodulatory biomaterials for type 1 diabetes.Nature reviews. Materials · 2019Article
- Influences of nanocarrier morphology on therapeutic immunomodulation.Nanomedicine (London, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Macroencapsulation is a powerful approach to increase the efficiency of extrahepatic pancreatic islet transplant. FTY720, a small molecule that activates signaling through sphingosine-1-phosphate receptors, is immunomodulatory and pro-angiogenic upon sustained delivery from biomaterials. While FTY720 (fingolimod, Gilenya) has been explored for organ transplantation, in the present work the effect of locally released FTY720 from novel nanofiber-based macroencapsulation membranes is explored for islet transplantation. We screened islet viability during culture with FTY720 and various biodegradable polymers. Islet viability is significantly reduced by the addition of high doses (≥500 ng/mL) of soluble FTY720. Among the polymers screened, islets have the highest viability when cultured with poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV). Therefore, PHBV was blended with polycaprolactone (PCL) for mechanical stability and electrospun into nanofibers. Islets had no detectable function ex vivo following 5 days or 12 h of subcutaneous implantation within our engineered device. Subsequently, we explored a preconditioning scheme in which islets are transplanted 2 weeks after FTY720-loaded nanofibers are implanted. This allows FTY720 to orchestrate a local regenerative milieu while preventing premature transplantation into avascular sites that contain high concentrations of FTY720. These results provide a foundation and motivation for further investigation into the use of FTY720 in preconditioning sites for efficacious islet transplantation. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 555-568, 2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.